INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
The first international trial of an unproven stroke treatment available in the U.S. has concluded that, while harmless, "perispinal" etanercept—injected into the spinal area—is no more effective than ...
In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents—and many more are considering following suit. The first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results